TY - DATA T1 - Additional file 1:Table S1. of A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post-hoc results from the certolizumab pegol phase 4 PREDICT trial PY - 2017/09/29 AU - Jeffrey Curtis AU - Christopher Herrem AU - ’Matladi Ndlovu AU - Cathy O’Brien AU - Yusuf Yazici UR - https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_Table_S1_of_A_somatization_comorbidity_phenotype_impacts_response_to_therapy_in_rheumatoid_arthritis_post-hoc_results_from_the_certolizumab_pegol_phase_4_PREDICT_trial/5457793 DO - 10.6084/m9.figshare.c.3893260_D1.v1 L4 - https://ndownloader.figshare.com/files/9436210 KW - Rheumatoid arthritis KW - Disease activity KW - Patient-reported outcomes KW - Comorbidities KW - Depression KW - Anxiety KW - Fibromyalgia KW - RAPID3 KW - CDAI N2 - SCP categories and medical history/diagnoses at baseline, with missing data handled by non-responder imputation (NRI). Table S2. Patients withdrawn from the study at/before and after week 12 due to lack of efficacy. Figure S1. Mean DAS28(ESR) score by SCP status, with missing data handled by last observation carried forward (LOCF). Full analysis set. (DOCX 1302 kb) ER -